Could buying these ASX shares at $9 now be like investing in Tesla in 2010?

This Melbourne company is making big strides in its field and has returned a phenomenal 67% each year for its investors already.

| More on:
A man in his 30s holds his laptop and operates it with his other hand as he has a look of pleasant surprise on his face as though he is learning something new or finding hidden value in something on the screen.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

I discussed earlier this month how it took a while for Tesla Inc (NASDAQ: TSLA) to become a brand name synonymous with the entire electric vehicle industry.

Those investors courageous enough to buy split-adjusted US$1.13 shares at the initial public offering (IPO) in 2010 have now been handsomely rewarded.

A $10,000 purchase of Tesla stocks back then would now be worth an amazing $2.13 million.

The point of bringing up that journey is not to annoy you that you missed out on the sweet action. Rather it serves to highlight how backing outstanding businesses early on and persisting for the long term can produce incredible riches.

While no one knows what will happen in the future, there are ASX shares with the potential to execute Tesla-esque growth in the years to come.

Let's break down one such candidate:

Revenue up 9x, share price up 13x

Telix Pharmaceuticals Ltd (ASX: TLX) makes diagnostic and treatment products for cancer.

The last 18 months have been a whirlwind for the Melbourne business.

Its prostate cancer imaging agent Illuccix went commercial last year, while products for other forms of cancer are undergoing trials or approval stages.

Revenue was, incredibly, up nine-fold in the 2023 financial year compared to the year before. And despite having so many products still progressing through the pre-commercial stages, Telix was cash flow positive.

Therefore it may not surprise you that the Telix share price has already multiplied 13 times over the past five years.

That's a crazy compound annual growth rate (CAGR) of 67%.

How's the outlook for these ASX shares?

Despite the explosive growth already behind it, there are plenty of reasons to suggest Telix could keep going over the next few years.

The first is all that revenue growth came from just one product, Illuccix. The company has many others in development, to deal with cancers in different parts of the body.

Of course, there is no guarantee they will all make it out the other side of medical trials and regulatory approvals. But even if some of them can join Illuccix as a paying product in the coming years, Telix's investors will be very happy.

The other ace up Telix's sleeve is that it has the balance sheet to make acquisitions.

In fact, it has already started playing this card. 

Just this week the business announced the acquisition of US outfit Qsam Biosciences, which is developing therapies for various types of cancer. At the start of this month, Telix completed the takeover of surgery technology provider Lightpoint Medical.

Many professional investors are believers in Telix.

According to CMC Markets, all seven analysts that cover the stock currently rate it as a buy.

Motley Fool contributor Tony Yoo has positions in Telix Pharmaceuticals. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals and Tesla. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Growth Shares

A young well-dressed couple at a luxury resort celebrate successful life choices.
Growth Shares

Where to invest $2,500 in ASX shares in August

Let's see which shares are being tipped as buys for next month.

Read more »

Person pointing at an increasing blue graph which represents a rising share price.
Growth Shares

What to buy now with the ASX at a record high

Analysts think these shares could still rise strongly from current levels.

Read more »

A young man looks at a stylised investment graph superimposed on an exterior office building backdrop.
Growth Shares

Where to invest $10,000 in ASX 200 stocks today

Analysts think these high-quality shares are in the buy zone for investors right now.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Growth Shares

Two ASX industrials shares with buy recommendations

One broker believes these growth shares are set to rise.

Read more »

Man smiling at a laptop because of a rising share price.
Growth Shares

I think these 2 exciting ASX growth shares are buys today

These stocks could deliver big returns.

Read more »

a man in a business suit and carrying a laptop stands smiling with hand in pocket outside a large office building in a city environment.
Growth Shares

Buy these 2 impressive ASX 200 shares in July: experts

Experts are bullish about these two businesses.

Read more »

A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face over these rising Tassal share price
Growth Shares

3 ASX 200 shares set to dominate the next decade

Let's see why these shares could be great long term picks for Aussie investors.

Read more »

A group of businesspeople clapping.
Growth Shares

3 ASX growth shares with 10-year compounding potential

Let's see which shares are being tipped as buys for growth investors.

Read more »